AstraZeneca has created an antibody treatment to prevent COVID-19 and is seeking FDA approval.
The treatment us called AZD7442 and works as a long-acting antibody combination.
If the authorization is granted, it can be used for immunocompromised people.
The formula boosts immunity for up to a year, where other drugs last a month or two.
There are three other drugs the FDA has approved, but all work to help or treat COVID symptoms.
This drug will prevent COVID.
Data from trials shows a reduced risk for symptomatic COVID of 77%. Three quarters of trial participants had conditions that suppressed their immunity.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]